Cart
×
CureDuchenne Cares Improves Standard of Care and Clinical Trial Education Throughout the U.S. for Families Affected by Duchenne
2017 CureDuchenne Cares Schedule Announced
Deflazacort Transition Program Reminder
Marathon submitted New Drug Applications (NDAs) to the Food and Drug Administration (FDA) last June for deflazacort. The NDAs have been accepted for filing and review. The FDA expects […]
CureDuchenne to Host Webinar with TRiNDS on a New Solution for the Duchenne Research Community
NEWPORT BEACH, Calif., January 16, 2017 – CureDuchenne, a nonprofit dedicated to funding research and improving patient care for Duchenne muscular dystrophy, will host a webinar with TRiNDS, a new […]
“We didn’t know anything about Duchenne and felt isolated that there was no one we could turn to, other than the doctors or the internet for advice, inspiration, or HOPE…”
August 8, 2011 was the day we first heard the word Duchenne. Every moment of that day is etched in my memory. We were hit out of the blue with […]
BioMarin Transfers Duchenne Natural History Database to CureDuchenne To Improve Knowledge of Duchenne Patients and Improve Clinical Outcomes
NEWPORT BEACH, Calif., January 10, 2017 – CureDuchenne announced today that BioMarinPharmaceutical Inc. has transferred its Duchenne natural history database to CureDuchenne, the venture philanthropy not-for-profit organization that is leading […]
“We joined CureDuchenne more than a decade ago in their mission to find a cure for Duchenne. We partnered with CureDuchenne because they are steadfast in identifying and funding promising research…”
When our two sons Timothy, 13, and Andrew, 10, were diagnosed with Duchenne muscular dystrophy there was little hope. We were told there was no cure or treatment and that […]
CureDuchenne Ventures Invests in TRiNDS to Provide Clinical Trial Solutions for Neuromuscular Disorders
NEWPORT BEACH, Calif., Dec. 19, 2016 – CureDuchenne Ventures, LLC, a company that funds research to find a cure for Duchenne muscular dystrophy, announced today that they invested inTRiNDS, LLC, […]
WE NEED YOUR HELP TO ADVANCE A TREATMENT TO CLINICAL TRIALS FOR RARE, DUPLICATION 2 MUTATIONS!
CureDuchenne has always been focused on finding and funding treatments to help EVERYONE affected with Duchenne, and to TREAT THE WHOLE DISEASE. We are very proud of our comprehensive portfolio […]
PFIZER CLINICAL TRIAL UPDATE
CureDuchenne is pleased to share the following updates from Pfizer pertaining to the on-going multicenter Phase II clinical trial of the investigational compound, domagrozumab (PF-06252616) in boys with Duchenne muscular […]